Tom Powles: Sacituzumab govitecan vs chemotherapy in heavily pretreated UC
Tom Powles, Professor at the University of London, posted the following on X:
“1/3 TROPICS-4: Sacituzumab govitecan vs chemotherapy in heavily pretreated UC.
OS & PFS HR of 0.86, not significance. RR 23 vs 14, but G3+ TRAE 67 vs 35% with G5 TRD. While there is activity, the toxicity and lower RR compared to EV/erda were problematic.
Debate about whether lack of prophylactic GCSF was responsible. But Deaths were still seen with GCSF prophylaxis. Heavily pretreated bladder cancer is a tough place to do trials due to comorbidities. This maybe different in other cancers and even in earlier bladder cancer.
Is this the end of SG or TROP-2/TOPO1 ADCs in UC? It’s tough for SG and FDA withdrawal is justified, but studies show SG activity. It would be a shame to drop this class altogether. Other TROP2/TOPO1 ADCs (D-DXD, MK2870) may have a different tox due to linker.”
Professor Thomas Powles, specializing in urology cancer, holds the position of Professor at the University of London since 2012 and serves as the Director of Barts Cancer Centre, a CRUK Major Cancer Centre. With a role in biomarker development and drug strategies, he has secured multiple EMA and FDA approvals.
His achievements include advancing front-line immune/targeted therapy combinations in RCC and immune checkpoint inhibition in bladder cancer.
More posts featuring Tom Powles.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023